About us
A BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) is an integrated fund and award framework to accelerate the translation of early-stage drug discovery from academia to pharma. The goal of our BRIDGE pre-seed partnerships is to unlock the potential of academic innovation from therapeutic concept to investable data point by making our know-how in drug discovery, our technology platforms and matched funding readily available to academic researchers.
- Website
-
www.evotec.com
External link for Evotec BRIDGEs
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
Updates
-
Proud to share the launch of Aptadir Therapeutics with Giovanni Amabile as acting CEO. Further evidence of the impact that Extend | the National Technology Transfer Biotech Hub joint venture involving CDP Venture Capital SGR, Angelini Ventures and Evotec SE is having in translating great science into new commercial opportunities. Aptadir will further develop a ground-breaking platform, based on a novel class of RNA inhibitors for the treatment of cancer and genetic disorders, and has raised $1.6 million in pre-seed funding.
We are proud to announce the launch of Aptadir Therapeutics and the appointment of our Executive Chairman and acting CEO, Giovanni Amabile. Aptadir has a novel approach for intractable cancers and genetic conditions in both adults and children. Our platform is based on a landmark discovery of a new class of RNA inhibitors called DNMTs Interacting RNAs (DiRs) which can block aberrant DNA methylation at a single gene level, reactivating previously hypermethylated genes – a key feature in cancer and genetic disorders such as MDS and Fragile X Syndrome. The origin of our science is from 3 top international institutions The Beth Israel Deaconess Medical Center of the Harvard Medical School The Italian National Research Council (CNR) The Cancer Science Institute of Singapore And thank you to the support from CDP Venture Capital SGR, Angelini Ventures and Evotec SE, making us the very first investment of the Extend | the National Technology Transfer Biotech Hub joint venture. Follow us at Aptadir Therapeutics or visit our website at https://aptadir.com for more news about the company and our developing pipeline. #MyelodysplasticNeoplasms, #FragileX, #biopharma, #biotech #startups #rarediseases #companybuilding Giovanni Amabile Claudia Pingue Davide Santi Simone Braggio Antonio Felici Carlo Bertozzi Paolo Di Giorgio Lola Buono Annalisa D. Vittorio de Franciscis Daniel Tenen Marcin Kortylewski
-
I had a fantastic few days with my Novo Nordisk colleagues at the World Medical Innovation Forum (WMIF), sponsored by our LAB eN2 partner, Mass General Brigham Innovation. WMIF brings together global leaders to explore the latest opportunities and challenges in the investment landscape, key technological advancements, manufacturing, and regulatory hurdles. It was an exciting glimpse into the future of patient care. - Michael Draper, SVP Academic Partnerships at Evotec Keep following us and learn more about LAB eN² and the Academic BRIDGEs by visiting the website - https://hubs.ly/Q02RbGvy0 #researchneverstops #WMIF2024
-
-
Wonderful being able to spend time last week with our LAB eN2 partner Novo Nordisk brainstorming how LAB eN2 can further accelerate the translation of academic ideas to therapeutic product candidates in the cardiometabolic space. Patients are waiting!!! Keep following us and learn more about LAB eN² and the Academic BRIDGEs by visiting the website - https://hubs.ly/Q02R2Bqr0 #researchneverstops
-
-
Congratulations to #65LAB awardee Associate Professor Lena Ho and her team at Duke-NUS Medical School for their innovative work on therapeutic targets to treat chronic inflammation! Learn more about this great achievement here - https://lnkd.in/ghyRNnTF #researchneverstops
Thanks Lianhe Zaobao 联合早报 for spotlighting #65LAB awardee Dr. Lena Ho and her innovative work on chronic inflammation. At Duke-NUS Medical School, Dr. Ho and her team are pioneering the study of microproteins to develop new anti-inflammatory therapies. Their research could pave the way for treatments with fewer side effects for conditions like rheumatoid arthritis and inflammatory bowel disease. Read the full article here: https://lnkd.in/ghCwGViV ClavystBio Evotec BRIDGEs Leaps by Bayer Lightstone Ventures Polaris Partners Duke-NUS Medical School SPH Media
杜克国大医学院研究员获251万元资助 研究慢性炎症新疗法
zaobao.com.sg
-
Thanks to our #65LAB investor Polaris Partners for the invitation to participate in their recent Singapore Summit panel. Great discussions on the theme of Accelerating Healthcare Innovation for a Global Market, including the biggest challenges faced by academic researchers in translating their research and key considerations when sourcing innovative 65LAB therapeutics projects. Keep following us and learn more about the Academic BRIDGEs by visiting the website - https://hubs.ly/Q02Qp86s0 #researchneverstops #HealthcareInnovation
-
-
It is rewarding to see how the role of EXTEND, one of Evotec's BRIDGEs, is perceived as crucial in the Italian scientific landscape. In particular, the contribution of an industrial partner is considered of great value to promote the translational process through collaboration with universities and VCs. Keep following us and learn more about the Academic BRIDGEs by visiting the website - https://hubs.ly/Q02NYFKR0 #researchneverstops #TechTransfer
On August 28, Antonio Felici, VP Academic Partnerships at Evotec and EIR of EXTEND, was invited to talk on the role of Industrial Partners in supporting academic research and prepare projects to venture Funding. He delivered a presentation entitled: “Pharma Innovation & Business in Italy: Nurturing potentials in an underestimated environment thorough EXTEND, a unique structured partnership between Accademia, VC and Pharma” during the Technology Transfer dedicated session, involving Venture Funds, TTOs and Start-uppers at the SCI2024 XXVIII National Congress, organized by Società Chimica Italiana. 💬 "It has been a real great opportunity to share the remit of EXTEND, its operational structure and the results achieved so far. Involving an industrial partner since the very early phase of a project emerged as a crucial need during the discussion. Proud to see that EXTEND is considered as a key player for providing expert scientific support and the required level of funding to qualify the project based on those standards required by Ventures" - Antonio Felici Keep following us and learn more about EXTEND by visiting the website - https://extend-tt.vc/ #researchneverstops #TechTransfer #Innovation
-
-
Congratulations from all at Evotec to our partner Uli Stilz on being named as an Innovation Honoree under Fierce Biotech’s Fierce 50 for 2024. Uli is a tireless champion for #innovation and one of the driving forces behind Evotec's BRIDGEs partnership with Novo Nordisk - LAB eN2 – which develops new therapeutic opportunities from academic partners including Harvard, Yale, MGB and BIDMC. Keep following us and check the Fierce 50 report by visiting the website - https://hubs.ly/Q02PhVy30
Uli Stilz
fiercepharma.com
-
Efforts to discover and support innovative therapeutic solutions for the market never stop. The third TVO Pitch It! competition, organized by Beth Israel Deaconess Medical Center (BIDMC), presented a valuable opportunity to learn more about the innovative research happening at BIDMC. "BIDMC is one of our LAB eN² partners, and it was a real pleasure to be a judge at the 3rd TVO Pitch It! competition, part of BIDMC's annual Research Retreat. Great science and great people!" - Michael Draper, SVP Academic Partnerships at Evotec Keep following us and learn more about LAB eN² and the Academic BRIDGEs by visiting the website - https://hubs.ly/Q02NYFKR0 #researchneverstops
-
-
Associate Professor Lena Ho from Duke-NUS Medical School has been awarded US$1.85 million (approx. S$2.51 million) to further her team’s research in developing microproteins into therapeutic targets to treat chronic inflammation. She is the first scientist to receive funding from #65LAB, a unique partnership set up to drive scientific advancement and create new biotech ventures from Singapore. The award comprises US$ 1.5 million from 65LAB, and US$350,000 from Duke-NUS’ new incubator, LIVE Ventures. To learn more, read the press release here-https://hubs.ly/Q02JbpHs0 #ResearchNeverStops #TogetherForMedicinesThatMatter Duke-NUS Medical School ClavystBio Leaps by Bayer Lightstone Ventures Polaris Partners Polaris Innovation Fund
-